As of 2024-07-27, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -3.47. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 706.67 mil USD. RVNC's TTM EBITDA according to its financial statements is -203.83 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.1x | 13.3x |
| Forward P/E multiples | 17.2x - 21.3x | 20.4x |
| Fair Price | (36.41) - (36.14) | (35.68) |
| Upside | -1028.8% - -1021.9% | -1010.2% |
| Date | EV/EBITDA |
| 2024-07-26 | -3.47 |
| 2024-07-25 | -3.38 |
| 2024-07-24 | -3.47 |
| 2024-07-23 | -3.68 |
| 2024-07-22 | -3.51 |
| 2024-07-19 | -3.32 |
| 2024-07-18 | -3.33 |
| 2024-07-17 | -3.49 |
| 2024-07-16 | -3.64 |
| 2024-07-15 | -3.41 |
| 2024-07-12 | -3.29 |
| 2024-07-11 | -3.13 |
| 2024-07-10 | -2.95 |
| 2024-07-09 | -2.94 |
| 2024-07-08 | -2.89 |
| 2024-07-05 | -2.83 |
| 2024-07-03 | -2.83 |
| 2024-07-02 | -2.70 |
| 2024-07-01 | -2.78 |
| 2024-06-28 | -2.78 |
| 2024-06-27 | -2.78 |
| 2024-06-26 | -2.66 |
| 2024-06-25 | -2.66 |
| 2024-06-24 | -2.78 |
| 2024-06-21 | -2.82 |
| 2024-06-20 | -2.93 |
| 2024-06-18 | -2.89 |
| 2024-06-17 | -2.89 |
| 2024-06-14 | -2.90 |
| 2024-06-13 | -2.98 |
| 2024-06-12 | -3.01 |
| 2024-06-11 | -2.96 |
| 2024-06-10 | -2.86 |
| 2024-06-07 | -2.84 |
| 2024-06-06 | -2.94 |
| 2024-06-05 | -3.01 |
| 2024-06-04 | -2.95 |
| 2024-06-03 | -3.00 |
| 2024-05-31 | -2.91 |
| 2024-05-30 | -2.94 |
| 2024-05-29 | -2.89 |
| 2024-05-28 | -2.83 |
| 2024-05-24 | -2.85 |
| 2024-05-23 | -2.83 |
| 2024-05-22 | -2.95 |
| 2024-05-21 | -3.00 |
| 2024-05-20 | -3.08 |
| 2024-05-17 | -3.01 |
| 2024-05-16 | -3.08 |
| 2024-05-15 | -3.15 |